

## Worldpay

Price 277.80p

The US branch is a thorn in the group's side; no clear operating leverage before H2 17

Fair Value 278p vs. 290p (0%)

NEUTRAL

|                            |               |
|----------------------------|---------------|
| Bloomberg                  | WPG LN        |
| Reuters                    | WPG.L         |
| 12-month High / Low (p)    | 316.8 / 240.0 |
| Market Cap (GBP)           | 5,556         |
| Ev (BG Estimates) (GBP)    | 6,981         |
| Avg. 6m daily volume (000) | 9,885         |
| 3y EPS CAGR                | 32.6%         |

|                | 1 M  | 3 M   | 6 M   | 31/12/15 |
|----------------|------|-------|-------|----------|
| Absolute perf. | 0.8% | -6.3% | ns    | -9.6%    |
| Softw. & Comp. | 6.3% | -5.8% | 10.9% | -6.2%    |
| DJ Stoxx 600   | 7.4% | -7.7% | -6.0% | -7.7%    |

| YEnd Dec. (GBPm) | 2014  | 2015e | 2016e | 2017e |
|------------------|-------|-------|-------|-------|
| Sales            | 3,627 | 3,963 | 4,240 | 4,580 |
| % change         |       | 9.3%  | 7.0%  | 8.0%  |
| EBITDA           | 286   | 302   | 392   | 496   |
| EBIT             | 296.3 | 340.5 | 366.8 | 413.1 |
| % change         |       | 14.9% | 7.7%  | 12.6% |
| Net income       | 91.7  | 138.4 | 226.2 | 266.4 |
| % change         |       | 50.9% | 63.4% | 17.8% |

|                  | 2014   | 2015e | 2016e | 2017e |
|------------------|--------|-------|-------|-------|
| Operating margin | 8.2    | 8.6   | 8.7   | 9.0   |
| Net margin       | -1.4   | -0.8  | 3.4   | 4.7   |
| ROE              | 26.0   | -4.4  | 17.5  | 21.7  |
| ROCE             | 14.0   | 12.1  | 14.5  | 15.5  |
| Gearing          | -1,173 | 212.4 | 158.2 | 112.1 |

| (p)           | 2014  | 2015e | 2016e | 2017e |
|---------------|-------|-------|-------|-------|
| EPS           | 5.71  | 6.92  | 11.31 | 13.32 |
| % change      | -     | 21.1% | 63.4% | 17.8% |
| P/E           | 48.6x | 40.1x | 24.6x | 20.9x |
| FCF yield (%) | 0.0%  | 0.6%  | 1.7%  | 4.0%  |
| Dividends (p) | 0.00  | 0.00  | 1.78  | 2.69  |
| Div yield (%) | NM    | NM    | 0.6%  | 1.0%  |
| EV/Sales      | 2.2x  | 1.8x  | 1.6x  | 1.5x  |
| EV/EBITDA     | 27.3x | 23.1x | 17.4x | 13.5x |
| EV/EBIT       | 26.4x | 20.5x | 18.7x | 16.1x |

Worldpay is struggling in the US (49% of group's sales), so the poor lfl top-line growth associated cannot create any leverage on its proprietary platform. We see no way out as the management does not intend to sell this division, whereas the market is consolidating. The real leverage on profitability won't be visible until H2 17e (once investment in its technology platforms is complete, i.e. Worldpay fully independent from RBS). WP's fundamentals are not impressive for the Payments sector (lfl sales growth, EBITDA and EBIT margin, FCF, financial position). We have revised downward our restated FY16/17e EPS sequence by 3.0% on average. Neutral rating reiterated and FV cut from 290p to 278p.

## ANALYSIS

- Worldpay is suffering in the US.** With an EBITDA margin of only 3.2% (-130bps), Worldpay US is putting the whole group's profitability under pressure (EBITDA margin of 7.6% vs. >=20% for European peers). The lack of size in the US, which is 49% of its FY15 sales, prevents the group from generating a significant leverage on its proprietary platform (very fragmented market). We are not optimistic for Worldpay's future in this region as its direct local competitors are much stronger (consolidation in favour of the largest players, e.g. Heartland recently bought by Global Payments) and its heavy net debt position makes any major acquisition impossible in the short/medium term (gearing of 212% in FY15 and 158% in FY16e). The management does not intend to get rid of the US; on the contrary, it is investing in integrated payment solutions in this geographical area.
- No real operating leverage before H2 17.** Regarding Worldpay's investment plan in its technology platforms, the group remains dependent on RBS for the clearing & settlement components (vs. merchant servicing & data applications and clearing & settlement before). The company expects a completion during H1 2017 (vs. our -GBP1.3m and cons. of early 2017 into our model), as a result its investment program should still weigh in FY17, but to a lesser extent (its total investment plan from 2012 to 2017e should stand at around GBP500m).
- Lack of FCF generation.** Worldpay generated a positive FCF (GBP32.4m vs. our -GBP1.3m and consensus at -GBP2.1m), however the transformation rate for underlying EBIT into FCF was only 9.5% in FY15 and we expect 25.2% in FY16e, i.e. far from other PSPs (>=50% for European peers).
- Limited positive impact from its 5.9% stake in Visa Europe (bought by Visa Inc.).** Worldpay's estimated share of these proceeds could be up to GBP930m (EUR1.2bn vs. our est. of EUR1.249bn), breaking down into 45% in cash, 31% in Series B preferred stock in Visa Inc. and 24% in post-transaction earnout. However, as we outlined in our initiation report, only 10% will be retained by Worldpay i.e. up to GBP93m (EUR120m vs. our est. of EUR124.9m) and Bain and Advent will receive 90% (these private equity funds own 42% of Worldpay's share capital). This positive impact is only 1.7% of Worldpay's current market capitalisation (0.8% for the cash part).
- Does Worldpay really deserve a premium to its peers?** The group is benefiting from a rather resilient organic sales growth (+5.6% in FY15), a strong position in the UK (28% of its FY15 sales; #1 acquirer, with a normative EBITDA margin >15% despite a difficult market). That said, Worldpay still has much to prove since it released a 4th-year of net loss. Worldpay is not a growth story, but rather a story of medium-term margin improvement (via the end to its GBP500m plan to invest in its platforms which should be completed in H1 17e, and the rising share of e-commerce in its mix). When we initiated the coverage (1st February 2016), we already highlighted that, at that time's current price, the share had no margin for error, especially since we expected no EPS upward revisions either to our own figures or those of the consensus for 2016/17e.

## VALUATION

- We maintain our **Neutral rating and cut our FV from 290p to 278p** (DCF at 312p, peer comparison at 270p, SOTP at 251p). Despite our far-from-pessimistic estimates, the share is not cheap, even taking into account only EV/EBITDA (it trades at 17.4x in FY16e whereas in our SOTP it deserves 16.1x taking into account a 12.5% premium on the UK part). As a reminder, **Worldpay is above all a physical merchant processor and acquirer in the US and UK** (77% of its FY15 revenue).
- We advise investors to focus on EV/sales and EV/EBITDA multiples out to 2017e** given that investments in platforms bloat capex and D&A expenses, and therefore bloat EV/EBIT and P/E multiples (same vision for Worldline). We believe it will only be reliable **to reason in PEG once investment in the platforms is complete, namely as of 2018e**. The share is currently trading on an average premium of 15% to its peers for 2016/17e but it clearly does not deserve any.



## NEXT CATALYSTS

- **AGM:** 10th May, 2016.

It seems essential to us to calculate Worldpay's profitability on: **1/ gross sales and not net sales**, which artificially boost its margin rate and make comparison with other European players in the sector inappropriate; **2/ EBITDA reported by the group rather than underlying EBITDA**. Indeed, the numerous negative items that this latter excludes (cost of platform separation, reorganisation, costs linked to acquisitions) should be adjusted for solely at the EBIT level (underlying EBIT). **This is what the group's rivals do and what we have been used to for companies in the sector.**

### Revenue and underlying EBITDA breakdown by business unit in FY14 and FY15

| GBPm                                 | Worldpay US    |                | Worldpay UK    |                | Global eCom  |              | Total          |                |
|--------------------------------------|----------------|----------------|----------------|----------------|--------------|--------------|----------------|----------------|
|                                      | 2014           | 2015           | 2014           | 2015           | 2014         | 2015         | 2014           | 2015           |
| <b>Revenue</b>                       | <b>1,666.4</b> | <b>1,933.7</b> | <b>1,229.0</b> | <b>1,130.7</b> | <b>731.2</b> | <b>898.6</b> | <b>3,626.6</b> | <b>3,963.0</b> |
| In % of total revenue                | 45.9%          | 48.8%          | 33.9%          | 28.5%          | 20.2%        | 22.7%        | 100.0%         | 100.0%         |
| Y/Y change                           | 3.2%           | 16.0%          | 8.9%           | -8.0%          | 15.2%        | 22.9%        | 7.3%           | 9.3%           |
| Y/Y change (fl)                      | 7.1%           | 0.7%           | 8.9%           | -8.0%          | 15.2%        | 22.9%        | 9.2%           | 5.6%           |
| <b>Underlying EBITDA<sup>1</sup></b> | <b>75.4</b>    | <b>62.3</b>    | <b>156.1</b>   | <b>179.2</b>   | <b>161.5</b> | <b>184.2</b> | <b>374.7</b>   | <b>406.1</b>   |
| Margin                               | 4.5%           | 3.2%           | 12.7%          | 15.8%          | 22.1%        | 18.0%        | 10.3%          | 10.2%          |

<sup>1</sup> The group does not provide the reported EBITDA margin breakdown.

Sources: Company; Bryan, Garnier & Co.

### Main financial items from 2014 to 2017e

| GBPm                            | 2014           | 2015           | vs. BG         | vs. Cons.      | BG 2016e       | BG 2016e       | BG 2017e       | BG 2017e       |
|---------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
|                                 | (reported)     | (reported)     | 2015e          | 2015           | (old)          | (new)          | (old)          | (new)          |
| <b>Revenue</b>                  | <b>3,626.6</b> | <b>3,963.0</b> | <b>4,000.0</b> | <b>4,005.9</b> | <b>4,280.0</b> | <b>4,240.4</b> | <b>4,622.4</b> | <b>4,579.6</b> |
| Y/Y change                      | 7.3%           | 9.3%           | 10.3%          | 10.5%          | 7.0%           | 7.0%           | 8.0%           | 8.0%           |
| Y/Y change (fl)                 | 9.2%           | 5.6%           | 7.0%           | N/A            | 7.0%           | 7.0%           | 8.0%           | 8.0%           |
| <b>Net revenue</b>              | <b>863.4</b>   | <b>981.7</b>   | <b>974.3</b>   | <b>972.7</b>   | <b>1,072.1</b> | <b>1,079.6</b> | <b>1,179.7</b> | <b>1,187.5</b> |
| Y/Y change                      | 7.9%           | 13.7%          | 12.8%          | 12.7%          | 10.0%          | 10.0%          | 10.0%          | 10.0%          |
| <b>EBITDA</b>                   | <b>286.1</b>   | <b>302.4</b>   | <b>304.0</b>   | <b>308.7</b>   | <b>402.3</b>   | <b>392.2</b>   | <b>505.7</b>   | <b>495.5</b>   |
| Margin                          | 7.9%           | 7.6%           | 7.6%           | 7.7%           | 9.4%           | 9.3%           | 10.9%          | 10.8%          |
| <b>Underlying EBITDA</b>        | <b>374.7</b>   | <b>406.1</b>   | <b>404.0</b>   | <b>406.9</b>   | <b>462.3</b>   | <b>452.2</b>   | <b>510.7</b>   | <b>500.5</b>   |
| Margin                          | 10.3%          | 10.2%          | 10.1%          | 10.2%          | 10.8%          | 10.7%          | 11.0%          | 10.9%          |
| <b>EBIT</b>                     | <b>125.0</b>   | <b>166.9</b>   | <b>159.0</b>   | <b>163.7</b>   | <b>261.1</b>   | <b>252.3</b>   | <b>353.2</b>   | <b>344.4</b>   |
| Margin                          | 3.4%           | 4.2%           | 4.0%           | 4.1%           | 6.1%           | 6.0%           | 7.6%           | 7.5%           |
| <b>Underlying EBIT</b>          | <b>296.3</b>   | <b>340.5</b>   | <b>335.0</b>   | <b>334.7</b>   | <b>376.6</b>   | <b>366.8</b>   | <b>422.5</b>   | <b>413.1</b>   |
| Margin                          | 8.2%           | 8.6%           | 8.4%           | 8.4%           | 8.8%           | 8.7%           | 9.1%           | 9.0%           |
| <b>Net profit</b>               | <b>-50.0</b>   | <b>-29.8</b>   | <b>-14.9</b>   | <b>-4.9</b>    | <b>149.5</b>   | <b>142.6</b>   | <b>222.6</b>   | <b>215.6</b>   |
| Margin                          | -1.4%          | -0.8%          | -0.4%          | -0.1%          | 3.5%           | 3.4%           | 4.8%           | 4.7%           |
| <b>Rest. net profit</b>         | <b>91.7</b>    | <b>138.4</b>   | <b>126.1</b>   | <b>139.2</b>   | <b>233.8</b>   | <b>226.2</b>   | <b>273.9</b>   | <b>266.4</b>   |
| Margin                          | 2.5%           | 3.5%           | 3.2%           | 3.5%           | 5.5%           | 5.3%           | 5.9%           | 5.8%           |
| <b>EPS (p)</b>                  | <b>-3.1</b>    | <b>-1.8</b>    | <b>-0.9</b>    | <b>-0.2</b>    | <b>7.5</b>     | <b>7.1</b>     | <b>11.1</b>    | <b>10.8</b>    |
| <b>Fully dil. rest. EPS (p)</b> | <b>5.7</b>     | <b>8.2</b>     | <b>6.3</b>     | <b>7.0</b>     | <b>11.7</b>    | <b>11.3</b>    | <b>13.7</b>    | <b>13.3</b>    |
| <b>FCF</b>                      | <b>0.7</b>     | <b>32.4</b>    | <b>-1.3</b>    | <b>-2.1</b>    | <b>116.5</b>   | <b>92.3</b>    | <b>228.6</b>   | <b>221.4</b>   |
| FCF/underlying EBIT             | 0.2%           | 9.5%           | -0.3%          | -0.6%          | 30.9%          | 25.2%          | 54.1%          | 53.6%          |
| <b>Net debt</b>                 | <b>2,254.1</b> | <b>1,425.3</b> | <b>1,384.3</b> | <b>1,389.5</b> | <b>1,232.1</b> | <b>1,287.2</b> | <b>1,044.7</b> | <b>1,113.8</b> |
| Gearing                         | -1,173.4%      | 212.4%         | 200.5%         | N/A            | 146.7%         | 158.2%         | 101.9%         | 112.1%         |

Sources: Company's consensus from 12 analysts (17/02/16); Bryan, Garnier & Co ests.

[Click here to download](#)



**Analyst :**  
Richard-Maxime Beaudoux  
33(0) 1.56.68.75.61  
rmbeaudoux@bryangarnier.com

**Sector Team :**  
Thomas Coudry  
Gregory Ramirez  
Dorian Terral

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

## Stock rating

|         |   |
|---------|---|
| BUY     | Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.      |
| NEUTRAL | Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.                     |
| SELL    | Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion. |

## Distribution of stock ratings

BUY ratings 63.4%

NEUTRAL ratings 29.1%

SELL ratings 7.5%

# Research Disclosure Legend

|    |   |  |     |
|----|---|--|-----|
| 1  | Bryan Garnier shareholding in Issuer            | Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").   | No  |
| 2  | Issuer shareholding in Bryan Garnier            | The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.   | No  |
| 3  | Financial interest                              | A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report   | No  |
| 4  | Market maker or liquidity provider              | A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.   | No  |
| 5  | Lead/co-lead manager                            | In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.  | No  |
| 6  | Investment banking agreement                    | A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.  | No  |
| 7  | Research agreement                              | A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.  | No  |
| 8  | Analyst receipt or purchase of shares in Issuer | The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.   | No  |
| 9  | Remuneration of analyst                         | The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.  | No  |
| 10 | Corporate finance client                        | In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.   | No  |
| 11 | Analyst has short position                      | The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.   | No  |
| 12 | Analyst has long position                       | The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.  | No  |
| 13 | Bryan Garnier executive is an officer           | A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.   | No  |
| 14 | Analyst disclosure                              | The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report. | Yes |
| 15 | Other disclosures                               | Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).   | No  |

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

| <b>London</b>                   | <b>Paris</b>                              | <b>New York</b>          | <b>Geneva</b>      | <b>New Delhi</b>     |
|---------------------------------|---|--------------------------|--------------------|----------------------|
| Beaufort House                  | 26 Avenue des Champs Elysées              | 750 Lexington Avenue     | rue de Grenus 7    | The Imperial Hotel   |
| 15 St. Botolph Street           | 75008 Paris                               | New York, NY 10022       | CP 2113            | Janpath              |
| London EC3A 7BB                 | Tel: +33 (0) 1 56 68 75 00                | Tel: +1 (0) 212 337 7000 | Genève 1, CH 1211  | New Delhi 110 001    |
| Tel: +44 (0) 207 332 2500       | Fax: +33 (0) 1 56 68 75 01                | Fax: +1 (0) 212 337 7002 | Tel +4122 731 3263 | Tel +91 11 4132 6062 |
| Fax: +44 (0) 207 332 2559       | Regulated by the                          | FINRA and SIPC member    | Fax+4122731 3243   | +91 98 1111 5119     |
| Authorised and regulated by the | Financial Conduct Authority (FCA) and     |                          | Regulated by the   | Fax +91 11 2621 9062 |
| Financial Conduct Authority     | the Autorité de Contrôle prudentiel et de |                          | FINMA              |                      |
| (FCA)                           | resolution (ACPR)                         |                          |                    |                      |

#### **Important information**

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..